New Billionaire Focus: Longevity Biotech Gains Momentum
Posted by greg208 in Longevity & Anti-Aging - 2 points, 0 comments.
The article from Forbes talks about a growing trend of billionaires and venture capitalists moving out of AI and into longevity biotech, citing advances in genome editing, stem cells, and computational biology as the key drivers of this shift. It highlights several companies that are receiving significant funding and outlines how these technologies could one day reshape healthcare, agriculture and conservation.
I reckon it’s a bit of a mixed bag. On the one hand, the headline is spot on – the headlines are getting louder and the capital is pouring in. On the other hand, it feels a bit like hype without enough proof that these therapies will deliver on the promise of adding healthy years. The piece glosses over the regulatory hurdles and the long time‑frames needed for clinical translation. From my own experience with peptides, I’ve seen how a lot of buzz can swing into speculation rather than real progress.
Does anyone else think the current funding surge is enough to push us into real clinical outcomes within the next few years, or are we just witnessing a new bubble?
Community discussion - research and educational context only. Not medical advice.